[1] World Health Organization. Coronavirus disease (COVID-19) outbreak (https://www.who.int).
[2] 胡利琳,王玮珺,朱清静,等.新型冠状病毒肺炎相关肝损伤:病因分析及治疗策略.中华肝脏病杂志,2020,28:97-99.
[3] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet,2020,395:497-506.
[4] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet,2020,395:507-513.
[5] 关贵文,高林,王建文,等.新型冠状病毒感染肺炎患者肝酶异常的机制探究.中华肝脏病杂志,2020,28:100-106.
[6] Fan ZY, Chen LP, Li J, et al.Clinical Features of COVID-19-Related Liver Damage. medRxiv,2020, in press. doi: 10.1101/2020.02.26.20026971.
[7] 国家卫生健康委员会.新型冠状病毒感染的肺炎诊疗方案(试行,第七版) .(http://www.nhc.gov.cn/)
[8] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA,2020:e201585.
[9] Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med,2020:10.1056/NEJMoa2002032.
[10] Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ,2020,368:m792.
[11] LU HZ, AI JW, SHEN YZ, et al. A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention.medRxiv,2020, in press.doi:10.1101/2020.02.19.20025031.
[12] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med,2020: S2213-2600(20)30079-5.
[13] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol,2020:S2468-1253(20)30057-1.
[14] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome.?Lancet Respir Med, 2020: S2213-2600(20)30076-X.
[15] Chai X, Hu L, Zhang Y, et al.Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. Bioxiv,2020, in press.doi:10.1101/2020.02.03.931766.
[16] Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med,2020,382:929-936.
[17] Tisoncik JR, Korth MJ, Simmons CP,et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev,2012,76:16-32.
[18] Chen J, Subbarao K. The Immunobiology of SARS. Annu Rev Immunol, 2007,25:443-472.
[19] Zhang XJ, Cheng X, Yan ZZ, et al. An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury.Nat Med, 2018,24:73-83.
[20] Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology,2010,52:1143-1155.
[21] Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol,2016,64:234-238.
[22] 胡小英,邓永强,朱芳.利巴韦林致大疱性表皮松解坏死型药疹合并肝炎、急性心肌炎1例.西北国防医学杂志,2015,36:538.
[23] 杨瑾,莫国栋,卢志军,等.我院107例干扰素注射液不良反应特点分析.今日药学, 2017, 27:199-201.
[24] 罗敏,胡巧织,肖桂荣,等.基于FAERS的新型冠状病毒肺炎治疗用药安全信号挖掘研究:磷酸氯喹.医药导报,2020:1-14.
[25] Low EXS, Zheng Q, Chan E, et al. Drug induced liver injury: East versus West - a systematic review and meta-analysis. Clin Mol Hepatol,2019:10.3350/cmh.2019.1003.
[26] Ahmad J, Odin JA. Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity.Clin Liver Dis,2017,21:55-72.
[27] Bühler T, Medinger M, Bouitbir J,et al.Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient. Front Pharmacol,2019,10:645.
[28] 骆抗先.乙型肝炎基础和临床.第3版.北京.人民卫生出版社,2006:702.
[29] Wan YM, Wu JF, Li YH, et al. Prednisone is not beneficial for the treatment of severe drug-induced liver injury: An observational study (STROBE compliant). Medicine (Baltimore),2019,98:e15886.
[30] McPherson S, Lucey MR, Moriarty KJ. Decompensated alcohol related liver disease: acute management. BMJ,2016,352:i124.
[31] Luo SH, Liu W, Liu ZJ, et al. Confirmed asymptomatic carrier of SARS-CoV-2.ChinaXiv,2020: 202002.00073.
[32] Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol,2008,14:6774-6785.
[33] 古敏,刘娇,史楠楠,等.中医药分期防治新型冠状病毒肺炎的药性功效分析. 中国中药杂志,2020:1-8.
[34] 李晓骄阳,李雅静,葛俊德,等.注重新型冠状病毒肺炎(COVID-19)治疗中药物性肝损伤的预警与保护.中草药,2020:1-9.
[35] 周翠,陈向荣.药物性肝损害诱发慢性肝病至重型肝炎19例临床分析.肝脏,2010,15:232. |
